AEON Biopharma closes $20M public offering; net proceeds ~$18.3M

AEON Biopharma, Inc.

Gross proceeds ~$20M from 40M common units at $0.50/unit (1 share + 1 Series A + 1 Series B warrant).
Net proceeds after underwriting fees ~$18.3M; over-allotment added 6M Series A and 6M Series B warrants.
Funds expected to support operations through 2025 and advance ABP-450 biosimilar development.
After offering, shares outstanding ~79.97M; warrants exercisable at $0.625/share post-stockholder approval.
CEO Marc Forth highlighted sufficient capital for 351(k) regulatory pathway and planned BPD Type 2 meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.